Vazyme released its 2026 interim report on August 28, 2026. The company's total operating revenue was RMB 700 million, and net profit attributable to the parent company was RMB 10.9625 million, ranking 28th among disclosed peer companies. Net cash inflow from operating activities was RMB 24.3047 million, ranking 22nd. The company's latest asset-liability ratio was 22.22%, gross margin was 70.26%, down 0.78 percentage points from the previous quarter, ROE was 0.30%, and diluted earnings per share was RMB 0.03. The number of shareholders was 11,300, and the top ten shareholders held 73.82% of the total share capital.
Nanjing Vazyme Biotech Co LtdInterim report shows modest net profit and declining gross margin, with no clear positive or negative catalyst.
